Thomas Huenig
Director/Miembro de la Junta en TeGenero AG .
Cargos activos de Thomas Huenig
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
TeGenero AG
 TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Director/Miembro de la Junta | 01/06/2000 | - |
Historial de carrera de Thomas Huenig
Formación de Thomas Huenig.
| Wuerzburg Schweinfurt University of Applied Sciences | Doctorate Degree |
Estadísticas
Internacional
| Alemania | 3 |
Operativa
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Huenig
- Experiencia